



uniQure to Participate in Multiple Upcoming Industry Conferences in September

September 7, 2021

LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- [uniQure N.V.](#) (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

- **Citi's 16th Annual BioPharma Virtual Conference, September 8 - 10, 2021**
 - Members of uniQure's management team, including [Matt Kapusta](#), chief executive officer, will participate in virtual one-on-one investor meetings throughout the day on Thursday, September 9.
- **Wells Fargo 2021 Virtual Healthcare Conference, September 9 - 10, 2021**
 - Members of uniQure's management team will participate in virtual one-on-one investor meetings throughout the day on Friday, September 10.
 - A fireside chat with Matt Kapusta will take place the same day from 12:00 to 12:30 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the [Investors & Newsroom](#) section of the uniQure website.
- **H.C. Wainwright 23rd Annual Global Investment Conference, September 13 - 15, 2021**
 - Members of uniQure's management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, September 15.
 - A pre-recorded fireside chat with Matt Kapusta will be available on September 13th through H.C. Wainwright or can be accessed through the link displayed in the [Investors & Newsroom](#) section of the uniQure website.
- **SVB Leerink CybeRx Series: Neuromuscular, Rare Disease & Genetic Medicines Summit, September 22 - 23, 2021**
 - Members of uniQure's management team including [Ricardo Dolmetsch, Ph.D.](#), president of Research & Development will participate in virtual one-on-one investor meetings throughout the day on Thursday, September 23.
- **2021 Cantor Virtual Global Healthcare Conference, September 27 - 30, 2021**
 - Members of uniQure's management team will participate in virtual one-on-one investor meetings throughout the day on Monday, September 27.
 - Ricardo Dolmetsch will participate in a fireside chat the same day at 9:20 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the [Investors & Newsroom](#) section of the uniQure website.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a [pipeline](#) of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington's disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer's, Parkinson's, and ALS. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:

Maria E. Cantor
Direct: 339-970-7536

Chiara Russo
Direct: 617-306-9137

FOR MEDIA:

Tom Malone
Direct: 339-970-7558

m.cantor@uniQure.com

c.russo@uniQure.com

t.malone@uniQure.com